Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. reduced its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 22.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,232 shares of the company’s stock after selling 18,000 shares during the period. Axsome Therapeutics makes up approximately 1.2% of Privium Fund Management B.V.’s portfolio, making the stock its 18th biggest position. Privium Fund Management B.V.’s holdings in Axsome Therapeutics were worth $5,265,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of AXSM. Assetmark Inc. purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the 4th quarter valued at approximately $64,000. KBC Group NV increased its holdings in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares during the last quarter. Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics in the third quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in Axsome Therapeutics during the third quarter worth $236,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $124.76 on Wednesday. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $6.08 billion, a PE ratio of -20.83 and a beta of 0.99. The business’s fifty day moving average price is $113.88 and its 200 day moving average price is $99.47.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AXSM shares. Needham & Company LLC reiterated a “buy” rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a report on Monday, March 3rd. Mizuho boosted their price target on shares of Axsome Therapeutics from $195.00 to $212.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 26th. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price objective for the company. Finally, StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $167.36.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.